Prognostic significance of ZNF217 expression in gastric carcinoma. 2014

Atsuo Shida, and Shuichi Fujioka, and Hideaki Kurihara, and Yoshio Ishibashi, and Norio Mitsumori, and Nobuo Omura, and Katsuhiko Yanaga
Department of Surgery, Jikei University School of Medicine, Tokyo, Japan atsuoshida@ybb.ne.jp.

BACKGROUND The zinc finger protein ZNF217 is a candidate oncogene in breast cancer and ovarian clear cell cancer. The purpose of the present study was to clarify the significance of this protein's expression in gastric carcinoma and to evaluate the outcome of these patients. METHODS Using paraffin-embedded specimens from 84 patients with gastric cancer, ZNF217 protein was detected using an anti-ZNF217 goat polyclonal antibody. We evaluated the ZNF217 protein expression in relation to patient outcome and clinicopathological parameters. RESULTS The ZNF217 protein was expressed in 34 (40.5%) tumor sections. Patients with ZNF217-negative tumors had better relapse-free survival (RFS) and overall survival (OS) than those with ZNF217-positive tumors by the log-rank test. Notably, multivariate analysis indicated that ZNF217 was an independent prognostic factor for RFS. CONCLUSIONS ZNF217 expression seems to be a novel prognostic biomarker in gastric cancer.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Atsuo Shida, and Shuichi Fujioka, and Hideaki Kurihara, and Yoshio Ishibashi, and Norio Mitsumori, and Nobuo Omura, and Katsuhiko Yanaga
January 1994, Anales de la Real Academia Nacional de Medicina,
Atsuo Shida, and Shuichi Fujioka, and Hideaki Kurihara, and Yoshio Ishibashi, and Norio Mitsumori, and Nobuo Omura, and Katsuhiko Yanaga
June 2004, Digestive diseases and sciences,
Atsuo Shida, and Shuichi Fujioka, and Hideaki Kurihara, and Yoshio Ishibashi, and Norio Mitsumori, and Nobuo Omura, and Katsuhiko Yanaga
October 2004, Cancer research and treatment,
Atsuo Shida, and Shuichi Fujioka, and Hideaki Kurihara, and Yoshio Ishibashi, and Norio Mitsumori, and Nobuo Omura, and Katsuhiko Yanaga
December 2007, Annals of surgical oncology,
Atsuo Shida, and Shuichi Fujioka, and Hideaki Kurihara, and Yoshio Ishibashi, and Norio Mitsumori, and Nobuo Omura, and Katsuhiko Yanaga
January 2020, Anticancer research,
Atsuo Shida, and Shuichi Fujioka, and Hideaki Kurihara, and Yoshio Ishibashi, and Norio Mitsumori, and Nobuo Omura, and Katsuhiko Yanaga
August 2000, Annals of surgical oncology,
Atsuo Shida, and Shuichi Fujioka, and Hideaki Kurihara, and Yoshio Ishibashi, and Norio Mitsumori, and Nobuo Omura, and Katsuhiko Yanaga
March 2015, Medical oncology (Northwood, London, England),
Atsuo Shida, and Shuichi Fujioka, and Hideaki Kurihara, and Yoshio Ishibashi, and Norio Mitsumori, and Nobuo Omura, and Katsuhiko Yanaga
January 1999, Anticancer research,
Atsuo Shida, and Shuichi Fujioka, and Hideaki Kurihara, and Yoshio Ishibashi, and Norio Mitsumori, and Nobuo Omura, and Katsuhiko Yanaga
December 1996, Cancer,
Atsuo Shida, and Shuichi Fujioka, and Hideaki Kurihara, and Yoshio Ishibashi, and Norio Mitsumori, and Nobuo Omura, and Katsuhiko Yanaga
May 1996, Cancer,
Copied contents to your clipboard!